A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
Outlook Therapeutics, Inc.
OTLK
$49M
Mkt Cap
$1.40
+6.44%
Outlook Therapeutics, Inc. (OTLK) has a 5-year average return on invested capital (ROIC) of -178.7%. This is below average and may indicate limited pricing power.
Outlook Therapeutics, Inc. (OTLK) has a market capitalization of $91M. It is classified as a small-cap stock.
Outlook Therapeutics, Inc. (OTLK) does not currently pay a regular dividend.
Outlook Therapeutics, Inc. (OTLK) operates in the Biological Products, (No Diagnostic Substances) industry, within the Healthcare sector.
Outlook Therapeutics, Inc. (OTLK) generated $-52 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Outlook Therapeutics, Inc. (OTLK) reported earnings per share (EPS) of $-1.79 in its most recent fiscal year.
Outlook Therapeutics, Inc. (OTLK) has a return on equity (ROE) of 118.6%. This indicates the company generates strong returns for shareholders.
We are a biopharmaceutical company that has developed ONS-5010/LYTENAVATM as the first ophthalmic formulation of bevacizumab approved by the European Commission in the European Union, or EU, and the Medicines and Healthcare products Regulatory Agency, or MHRA, in the United Kingdom, or UK, for use in adults for the treatment of wet age-related macular degeneration, or wet AMD. In June 2025, we launched directly into the initial markets of Germany and the UK. Additionally, our Biologics License Application, or BLA, is currently under review at the U.S. Food and Drug Administration, or FDA, for the use of ONS-5010/LYTENAVA as a treatment for wet AMD in the United States. If approved by the FDA., our goal is to also launch directly in the United States as the first and only approved ophthalmic bevacizumab for the treatment of wet AMD. In addition to Europe and the United States., we may seek approval to launch ONS-5010/LYTENAVA the product in other markets.
| Segment | 2025 | % of Total |
|---|---|---|
Development and commercialization of ONS-5010/LYTENAVA | $1M | 100% |
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 1.4M | - | - | - | - | - |
| Net Income | -103M | -62M | -75M | -59M | -66M | -53M |
| EPS | $-2.48 | $-1.79 | $-4.06 | $-2.49 | $-3.41 | $-3.85 |
| Free Cash Flow | 0 | -52M | -69M | -43M | -57M | -54M |
| ROIC | -255.3% | -285.1% | -196.5% | -164.5% | -174.7% | -179.1% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | -1.58 | -1.39 | -0.00 | 0.00 | 0.01 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -59M | -67M | -72M | -53M | -63M | -52M |
| Operating Margin | -4319.0% | - | - | - | - | - |
| ROE | 0.0% | 118.6% | 172.2% | - | -756.0% | -1153.9% |
| Shares Outstanding | 65M | 35M | 19M | 24M | 19M | 14M |
| Metric | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 1.4M |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D | 39M | 33M | 24M | 19M | 24M | 26M | 39M | 42M | 26M | 42M | 27M | 21M |
| SG&A | 13M | 22M | 16M | 14M | 9.4M | 10.0M | 13M | 21M | 27M | 30M | 40M | 37M |
| EBIT | -47M | -51M | -36M | -30M | -36M | -37M | -52M | -63M | -53M | -72M | -67M | -59M |
| Op. Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -4319.0% |
| Net Income | -53M | -63M | -40M | -48M | -36M | -49M | -53M | -66M | -59M | -75M | -62M | -103M |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -7537.5% |
| Non-Recurring | 0 | -14K | -62K | 0 | 11M | 528K | 0 | 0 | 0 | 0 | 2.9M | 2.9M |
| Returns on Capital | ||||||||||||
| ROIC | -133.0% | -159.7% | -173.1% | -133.0% | -167.4% | -186.7% | -179.1% | -174.7% | -164.5% | -196.5% | N/M | N/M |
| ROE | 97.7% | 212.6% | 206.2% | 162.2% | 173.0% | -1729.3% | -1153.9% | -756.0% | N/A | 172.2% | 118.6% | 0.0% |
| ROA | -151.4% | -209.0% | -173.5% | -223.3% | -182.9% | -265.1% | -249.9% | -257.3% | -193.9% | -246.6% | -263.4% | -564.0% |
| Cash Flow | ||||||||||||
| Op. Cash Flow | -27M | -45M | -16M | -33M | -32M | -32M | -54M | -57M | -43M | -69M | -52M | -56M |
| Free Cash Flow | -36M | -47M | -16M | -36M | -33M | -32M | -54M | -57M | -43M | -69M | -52M | 0 |
| Owner Earnings | -40M | -60M | -27M | -38M | -37M | -35M | -59M | -65M | -49M | -74M | -61M | -62M |
| CapEx | 8.8M | 1.1M | 292K | 2.8M | 437K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Maint. CapEx | 1.8M | 2.4M | 2.7M | 3.1M | 3.4M | 219K | 262K | 205K | 44K | 114K | 117K | 118K |
| Growth CapEx | 7.0M | 0 | 0 | 0 | 0 | N/A | N/A | N/A | N/A | N/A | N/A | 0 |
| D&A | 1.8M | 2.4M | 2.7M | 3.1M | 3.4M | 219K | 262K | 205K | 44K | 114K | 117K | 118K |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | ||||||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 11M | 12M | 8.6M | 2.0M | 1.3M | 2.8M | 4.9M | 7.7M | 5.5M | 5.4M | 8.9M | 6.1M |
| Debt Repayment | 726K | 1.1M | 2.7M | 128K | 6.4M | 48K | 50K | 12M | 10M | 0 | 36M | 36M |
| Balance Sheet | ||||||||||||
| Net Debt | 9.9M | 468K | -3.0M | -1.6M | -6.9M | -12M | -14M | -17M | -23M | N/A | N/A | -8.7M |
| Cash & Equiv. | 9.1M | 2.4M | 3.2M | 1.7M | 8.0M | 13M | 14M | 17M | 23M | 15M | 8.1M | 8.7M |
| Long-Term Debt | 2.9M | 2.2M | 151K | 98K | 50K | 42K | 16K | 4K | N/A | N/A | N/A | N/A |
| Debt/Equity | -0.35 | -0.55 | -0.01 | -0.01 | -0.07 | 0.03 | 0.01 | 0.00 | -0.00 | -1.39 | -1.58 | 0.00 |
| Interest Coverage | -20.3 | -27.7 | -6.4 | -7.6 | -10.5 | -21.0 | -55.3 | -42.4 | -21.0 | -22.7 | -236.9 | -236.9 |
| Equity | -54M | -5.2M | -34M | -26M | -16M | 2.8M | 4.6M | 8.7M | -14M | -73M | -32M | -39M |
| Total Assets | 35M | 25M | 21M | 22M | 17M | 20M | 23M | 29M | 32M | 29M | 19M | 18M |
| Total Liabilities | 90M | 31M | 54M | 48M | 33M | 17M | 18M | 20M | 47M | 102M | 51M | 57M |
| Intangibles | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | -94M | -147M | -186M | -216M | -254M | -290M | -343M | -409M | -468M | -543M | -606M | -629M |
| Working Capital | -22M | -15M | -25M | -29M | -6.8M | 2.1M | 15M | 7.8M | -16M | -15M | -28M | -32M |
| Current Assets | 15M | 5.7M | 3.9M | 3.3M | 14M | 18M | 22M | 28M | 31M | 27M | 17M | 17M |
| Current Liabilities | 37M | 20M | 29M | 32M | 20M | 16M | 6.8M | 20M | 47M | 43M | 46M | 49M |
| Per Share Data | ||||||||||||
| EPS | -59.73 | -40.37 | -19.80 | -12.42 | -10.89 | -7.37 | -3.85 | -3.41 | -2.49 | -4.06 | -1.79 | -2.48 |
| Owner EPS | -45.62 | -38.57 | -13.24 | -9.85 | -11.17 | -5.25 | -4.30 | -3.33 | -2.05 | -4.00 | -1.74 | -0.96 |
| Book Value | -61.11 | -3.31 | -16.65 | -6.60 | -4.87 | 0.43 | 0.33 | 0.45 | -0.61 | -3.94 | -0.92 | -0.60 |
| Cash Flow/Share | -30.97 | -29.08 | -7.67 | -8.54 | -9.76 | -4.79 | -3.93 | -2.93 | -1.82 | -3.71 | -1.49 | -1.59 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 0.9M | 1.6M | 2.0M | 3.9M | 3.3M | 6.6M | 13.8M | 19.4M | 23.7M | 18.6M | 34.9M | 64.6M |
| Valuation | ||||||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -0.6 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Sales | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 66.5 |
| FCF Yield | N/A | -0.4% | -0.3% | -0.3% | -6.3% | -3.3% | -0.8% | -1.1% | -3.8% | -19.3% | -153.2% | N/A |
| Market Cap | N/A | 11.8B | 5.1B | 13.3B | 517M | 964M | 6.7B | 5.2B | 1.1B | 356M | 34M | 91M |
| Avg. Price | N/A | 623.08 | 379.79 | 168.40 | 86.72 | 20.03 | 38.43 | 29.72 | 23.36 | 7.97 | 2.31 | 1.40 |
| Year-End Price | N/A | 683.20 | 228.80 | 156.80 | 28.40 | 13.22 | 44.00 | 24.40 | 4.36 | 5.56 | 0.97 | 1.40 |
Outlook Therapeutics, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
The Ledger Terminal provides 11 years of financial data for Outlook Therapeutics, Inc. (OTLK), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Outlook Therapeutics, Inc. (OTLK) has a book value per share of $-0.92, based on its most recent annual SEC filing.